Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/psychedelic-therapy.md — the filesystem corpus, unchanged. Not an edit.
17.7 kB
Revision 1
Revision 2
lines 8–14 → 8–147 unchanged lines not shown
categories: ["minds", "enhancement"]categories: ["minds", "enhancement"]tags: ["psilocybin", "mdma", "depression", "ptsd", "clinical trials", "blinding", "psychiatry"]tags: ["psilocybin", "mdma", "depression", "ptsd", "clinical trials", "blinding", "psychiatry"]summary: "The administration of serotonergic psychedelics or MDMA alongside psychological support for psychiatric conditions, in trials that cannot be reliably blinded."summary: "The administration of serotonergic psychedelics or MDMA alongside psychological support for psychiatric conditions, in trials that cannot be reliably blinded."updated: "2026-07-27"updated: "2026-10-29"humanEvidence: "Randomized trials in human patients report large short-term reductions in depression and PTSD symptoms, but participants and therapists almost always guess the assignment correctly, so drug and expectancy effects remain confounded."humanEvidence: "Randomized trials in human patients report large short-term reductions in depression and PTSD symptoms, but participants and therapists almost always guess the assignment correctly, so drug and expectancy effects remain confounded."access: "Esketamine is approved for treatment-resistant depression; psilocybin and MDMA remain unapproved medicines, reachable through trials or Australia's authorised-prescriber pathway, and psilocybin is sold at licensed non-medical centres in two US states."access: "Esketamine is approved for treatment-resistant depression; psilocybin and MDMA remain unapproved medicines, reachable through trials or Australia's authorised-prescriber pathway, and psilocybin is sold at licensed non-medical centres in two US states."reversibility: "context"reversibility: "context"lines 46–52 → 46–5231 unchanged lines not shown
```timeline```timeline[[ { "year": "1938–1943", "title": "LSD synthesised, then discovered", "text": "Albert Hofmann makes LSD at Sandoz in 1938 and identifies its psychoactivity five years later; the company distributes it to psychiatric researchers." }, { "year": "1938-1943", "title": "LSD synthesised, then discovered", "text": "Albert Hofmann makes LSD at Sandoz in 1938 and identifies its psychoactivity five years later; the company distributes it to psychiatric researchers." }, { "year": "1958", "title": "Psilocybin isolated", "text": "Hofmann isolates the active compound from Psilocybe mushrooms; Sandoz markets it to researchers as Indocybin." }, { "year": "1958", "title": "Psilocybin isolated", "text": "Hofmann isolates the active compound from Psilocybe mushrooms; Sandoz markets it to researchers as Indocybin." }, { "year": "1970", "title": "Schedule I in the United States", "text": "The Controlled Substances Act places LSD and psilocybin in the most restrictive category, and clinical work in the West effectively stops for two decades." }, { "year": "1970", "title": "Schedule I in the United States", "text": "The Controlled Substances Act places LSD and psilocybin in the most restrictive category, and clinical work in the West effectively stops for two decades." }, { "year": "1985", "title": "MDMA scheduled", "text": "The DEA places MDMA in Schedule I on an emergency basis, over objections from psychotherapists who had been using it; the placement is challenged in court and later made permanent." }, { "year": "1985", "title": "MDMA scheduled", "text": "The DEA places MDMA in Schedule I on an emergency basis, over objections from psychotherapists who had been using it; the placement is challenged in court and later made permanent." },lines 55–65 → 55–652 unchanged lines not shown
{ "year": "2019", "title": "Esketamine approved", "text": "The FDA approves esketamine nasal spray for treatment-resistant depression, restricted to certified clinics under a risk-management programme." }, { "year": "2019", "title": "Esketamine approved", "text": "The FDA approves esketamine nasal spray for treatment-resistant depression, restricted to certified clinics under a risk-management programme." }, { "year": "2021", "title": "A comparator and a phase 3", "text": "Psilocybin fails to beat escitalopram on the primary outcome of a head-to-head depression trial, while MAPS reports a positive phase 3 of MDMA-assisted therapy for PTSD." }, { "year": "2021", "title": "A comparator and a phase 3", "text": "Psilocybin fails to beat escitalopram on the primary outcome of a head-to-head depression trial, while MAPS reports a positive phase 3 of MDMA-assisted therapy for PTSD." }, { "year": "2023", "title": "Australia opens a pathway", "text": "The Therapeutic Goods Administration permits authorised psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression, the first such national framework." }, { "year": "2023", "title": "Australia opens a pathway", "text": "The Therapeutic Goods Administration permits authorised psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression, the first such national framework." }, { "year": "2024", "title": "The FDA declines", "text": "An advisory committee votes against MDMA-assisted therapy on both effectiveness and benefit–risk, and the agency asks Lykos Therapeutics, the renamed MAPS corporate arm, for an additional phase 3 trial." } { "year": "2024", "title": "The FDA declines", "text": "An advisory committee votes against MDMA-assisted therapy on both effectiveness and benefit-risk, and the agency asks Lykos Therapeutics, the renamed MAPS corporate arm, for an additional phase 3 trial." }]]`````` The first clinical wave, from the 1950s to about 1970, produced a large literature and little that survives scrutiny: open-label case series, token controls, outcomes chosen after the fact. Prohibition ended it before the methodology improved. The revival was built to avoid a repeat, which makes its central design flaw more striking, not less.The first clinical wave, from the 1950s to about 1970, produced a large literature and little that survives scrutiny: open-label case series, token controls, outcomes chosen after the fact. Prohibition ended it before the methodology improved. The revival was built to avoid a repeat, which makes its central design flaw all the more striking. ## Clinical evidence## Clinical evidence lines 73–79 → 73–797 unchanged lines not shown
A person given an active dose knows it within an hour, and so does the therapist sitting with them. Guess rates approach ceiling for both parties, which means the double-blind design that licenses causal inference in drug trials is not actually operating.[^muthu2021] Inert placebos are transparent; active comparators such as niacin or a very low dose of the same drug reduce the problem without removing it.A person given an active dose knows it within an hour, and so does the therapist sitting with them. Guess rates approach ceiling for both parties, which means the double-blind design that licenses causal inference in drug trials is not actually operating.[^muthu2021] Inert placebos are transparent; active comparators such as niacin or a very low dose of the same drug reduce the problem without removing it. The confound compounds. Participants are recruited from populations enthusiastic about psychedelics, arrive with strong expectations, and are assessed on scales that depend on their own report or a clinician's judgement rather than on anything measurable. The therapists are unblinded and typically advocates. Sham-controlled trials of [[non-invasive-neuromodulation]] and [[deep-brain-stimulation]] face a milder version of the difficulty, but no sham resembles several hours of altered consciousness.Recruitment and assessment compound the confound. Participants are recruited from populations enthusiastic about psychedelics, arrive with strong expectations, and are assessed on scales that depend on their own report or a clinician's judgement rather than on anything measurable. The therapists are unblinded and typically advocates. Sham-controlled trials of [[non-invasive-neuromodulation]] and [[deep-brain-stimulation]] face a milder version of the difficulty, but no sham resembles several hours of altered consciousness. > [!caution] What the FDA actually said> [!caution] What the FDA actually said> The 2024 rejection was not a safety refusal. The advisory committee's objections centred on functional unblinding, on the impossibility of separating the drug from an unstandardized psychotherapy the agency does not regulate, and on missing data about durability and abuse potential.[^lykos2024] In the same month the journal *Psychopharmacology* retracted three papers reporting earlier MDMA trial data, citing undisclosed unethical conduct at one site.> The 2024 rejection was not a safety refusal. The advisory committee's objections centred on functional unblinding, on the impossibility of separating the drug from an unstandardized psychotherapy the agency does not regulate, and on missing data about durability and abuse potential.[^lykos2024] In the same month the journal *Psychopharmacology* retracted three papers reporting earlier MDMA trial data, citing undisclosed unethical conduct at one site.lines 86–92 → 86–926 unchanged lines not shown
The second track is not medical. Oregon's Measure 109, passed in 2020, created a state-licensed psilocybin services programme, operating since 2023: adults may consume psilocybin with a trained facilitator at a licensed centre, with no diagnosis, no prescription, and no claim of treating anything. Colorado's Proposition 122 established a comparable healing-centre framework. Neither is an approval, neither generates controlled outcome data, and calling them legalized psychedelic medicine misstates what voters passed.The second track is not medical. Oregon's Measure 109, passed in 2020, created a state-licensed psilocybin services programme, operating since 2023: adults may consume psilocybin with a trained facilitator at a licensed centre, with no diagnosis, no prescription, and no claim of treating anything. Colorado's Proposition 122 established a comparable healing-centre framework. Neither is an approval, neither generates controlled outcome data, and calling them legalized psychedelic medicine misstates what voters passed. Cost constrains the medical track: the active ingredient is cheap, a full day of two clinicians' time is not, which places the intervention inside the problems catalogued in [[access-and-inequality]]. Scheduling from the first wave remains in force in most jurisdictions, an application of the [[precautionary-principle]] critics blame for decades of lost evidence.Cost constrains the medical track: the active ingredient is cheap but a full day of two clinicians' time is not, and that places the intervention inside the problems catalogued in [[access-and-inequality]]. Scheduling from the first wave remains in force in most jurisdictions, an application of the [[precautionary-principle]] critics blame for decades of lost evidence. ## Risks## Risks lines 102–113 → 102–1139 unchanged lines not shown
## Outlook## Outlook Three things would move the field. The first is the additional MDMA phase 3 the FDA requested, together with the psilocybin phase 3 programme, read for effect sizes rather than headlines. The second is a design that measures the drug's contribution instead of assuming it: prespecified expectancy assessment, blinded independent raters, dose–response comparisons among active arms. The third is pharmacological. Analogues engineered to keep the plasticity-promoting effects without the subjective experience have shown antidepressant-like effects in rodents; one that worked in humans would settle whether the experience is necessary and restore the blind at once.Three things would move the field. The first is the additional MDMA phase 3 the FDA requested, together with the psilocybin phase 3 programme, read for effect sizes rather than headlines. The second is a design that measures the drug's contribution instead of assuming it: prespecified expectancy assessment, blinded independent raters, dose-response comparisons among active arms. The third is pharmacological. Analogues engineered to keep the plasticity-promoting effects without the subjective experience have shown antidepressant-like effects in rodents; one that worked in humans would settle whether the experience is necessary and restore the blind at once. > [!debate] Is the trip required> [!debate] Whether the trip is required> One camp holds that the acute experience is the therapy, that its intensity predicts outcome, and that a non-hallucinogenic analogue would be a different drug. The other holds that the experience is a side effect of engaging a plasticity mechanism, and that the intensity–outcome correlation is what expectancy alone would produce. No human trial has separated them.> One camp holds that the acute experience is the therapy, that its intensity predicts outcome, and that a non-hallucinogenic analogue would be a different drug. The other holds that the experience is a side effect of engaging a plasticity mechanism, and that the intensity-outcome correlation is what expectancy alone would produce. No human trial has separated them. The strongest objection to the field is not that its drugs are dangerous or its trials fraudulent. It is that after two decades of revival, no study has distinguished the effect of the drug from the effect of believing one received it.The strongest objection to the field concerns neither danger nor fraud: after two decades of revival, no study has distinguished the effect of the drug from the effect of believing one received it. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
125 lines are the same in both revisions, and 84 of them are not shown. Neither revision here is necessarily the current article — read Psychedelic therapy for the text this wiki stands behind today.